Does Serotonin System Stimulation Increase Pro-social Behavior? - a Comparative Pharmacological Neuroscientific Study in Healthy Humans

University of Zurich (UZH)

Status and phase: Enrolling; Phase 1

Conditions: Healthy

Treatments: Drug: 3,4 Methylenedioxymethamphetamine; Drug: Methylphenidate; Drug: Psilocybin

Study type: Interventional

Funder types: Other

Identifiers

NCT06081179

2A-SC-1

Details and patient eligibility

About

The study looks into whether administering psychedelic substances that stimulate the serotonin system influences pro-social behavior when compared to administering substances that stimulate the dopamine system in healthy individuals.

Full description

Psychedelic substances have been shown to be powerful modulators of social perception and behavior during the acute experience. This is of particular interest given that social relationships play a key role in the development and resolution of psychiatric symptoms. However, the neuropharmacological mechanism underlying pro-social effects and time-dependent changes currently remain unclear. This study therefore aims at answering two key questions: 1) Does stimulation of the serotonin system induce lasting effects on pro-social behavior? and 2) Are these effects specific to serotonergic stimulation? The following proposed study will assess these questions by investigating objective, ecologically valid measures of pro-social cognition four weeks after different pharmacological challenges (MDMA, an entactogen and releaser of serotonin, norepinephrine, and dopamine; psilocybin: a classical psychedelic and serotonin 2A receptor agonist, methylphenidate: an amphetamine and norepinephrine-dopamine re-uptake inhibitor) in healthy volunteers.

Enrollment: 120 estimated patients

Sex: All

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male or female at the age of 18-40
• Willing and capable to give informed consent for study participation as documented by signature (Informed Consent Form) after the nature of the study has been thoroughly explained
• Willing to refrain from drinking alcohol the day before testing session, from drinking alcohol and caffeinated drinks at the testing days and from consuming psychoactive substances two weeks before the first investigation visit and for the duration of the study
• Willing to abstain from using drugs that may interfere with the effects of the study medications including sleeping aids, cough medications, beta-blocker or other substances with potentially relevant psychoactive and cardiovascular effects.
• Able and willing to comply with all study requirements
• Good physical health with no unstable medical conditions, as determined by medical history, physical examination, routine blood labs, electrocardiogram, urine analysis, and urine toxicology
• Women of childbearing potential (as defined by: 'the age of carrying or giving birth to a child', normally between 14-45 years of age, not in menopause, last menstrual period (LMP) less than 12 months, no removal of ovaries or uterus, no ligature of Fallopian tubes') must be using an effective, established method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices. Note: female participants who are surgically sterilized/hysterectomized or post-menopausal for longer than 2 years are not considered as being of childbearing potential
• Willing not to drive a traffic vehicle or to operate machines within 48h following substance administration
• Have a family member or friend who can pick them up after the substance administration sessions (driving is forbidden at drug treatment days)

Exclusion criteria

• Poor knowledge of the German language
• Previous significant adverse response to a hallucinogenic drug (incl. psilocybin), MDMA, or methylphenidate
• Allergy or hypersensitivity to previous use of MDMA, psilocybin, or methylphenidate
• Lifetime history of hallucinogen (incl. psilocybin), MDMA, or methylphenidate use on more than 10 occasions
• Personal and family history of major psychiatric disease (e.g., schizophrenia, schizoaffective disorder, psychosis, major depression, bipolar disorder, psychotic disorder, substance addiction/abuse other than caffeine and nicotine) as defined in the DSM-V (1st and 2nd degree relatives)
• History of suicidal behavior
• Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant
• Attention-Deficit/Hyperactivity-Disorder (ADHD)
• Any current major medical condition (e.g., neurologic, cardiovascular, metabolic, infectious disease) or any unstable illness as determined by medical history or laboratory tests
• Uncorrected hypo-or hyperthyroidism
• Uncorrected hypo-and hypertension
• Epilepsy
• Abnormal electrocardiogram
• BMI <17 or >35
• Personal history of head trauma, brain/cardiac surgery, fainting, or electroconvulsive therapy
• Personal and family history of seizure disorder and strokes (1st and 2nd degree relatives)
• Participation in another study where pharmaceutical compounds are given within the 30 days preceding and during the present study
• Current psychopharmacological treatment or medication that affects brain function
• Use of medications that are contraindicated or otherwise interfere with the effects of the study medications (monoamine oxidase inhibitors, antidepressants, sedatives etc.)
• Women who are pregnant or breast feeding, or have the intention to become pregnant during the study (for safety reasons, a urine pregnancy test will be done at the screening visit and before the substance administration)
• Enrollment of the investigator, his/her family members, employees, and other dependent persons

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

120 participants in 3 patient groups

Psilocybin

Active Comparator group

Description:

40 participants will receive psilocybin

Treatment:

Drug: Psilocybin

MDMA

Active Comparator group

Description:

40 participants will receive MDMA

Treatment:

Drug: 3,4 Methylenedioxymethamphetamine

Methylphenidate

Active Comparator group

Description:

40 participants will receive methylphenidate

Treatment:

Drug: Methylphenidate